第二代抗精神病药的滥用与误用:基于VigiBase药物警戒数据库的分析
该研究利用WHO VigiBase数据库评估第二代抗精神病药的滥用/误用潜力,提取截至2018年6月的滥用、依赖和戒断个案安全报告,通过信息成分(IC025)和比例报告比(PRR)评估不成比例报告。共识别1683份涉及第二代抗精神病药的报告,以喹硫平(n=1089)和奥氮平(n=209)为主。不成比例报告指标提示喹硫平、奥氮平和齐拉西酮与药物滥用和依赖相关,其中齐拉西酮为首次被highlight。
要点
- 喹硫平和奥氮平的滥用/误用潜力被确认,齐拉西酮的滥用/误用潜力首次被提示。
- 喹硫平IC025为2.263、PRR为3.929;奥氮平IC025为0.259、PRR为1.020;齐拉西酮IC025为1.051、PRR为1.334。
- 处方这些抗精神病药时应考虑滥用风险,尤其对有药物滥用史的患者。
核心结论
- 第二代抗精神病药中喹硫平和奥氮平的滥用/误用潜力被确认,齐拉西酮的滥用/误用潜力首次被提示。
研究设计与样本
- 研究基于WHO VigiBase药物警戒数据库,提取截至2018年6月涉及第二代抗精神病药的滥用、依赖和戒断个案安全报告,计算信息成分(IC025)和比例报告比(PRR)评估不成比例报告。
主要发现
- 共识别1683份记录为滥用、依赖和戒断且涉及第二代抗精神病药的个案安全报告,主要为喹硫平(n=1089)和奥氮平(n=209)。
- 不成比例报告指标显示药物滥用和依赖与喹硫平、奥氮平和齐拉西酮相关,IC025分别为2.263、0.259和1.051,PRR分别为3.929、1.020和1.334。
关键数值与推荐
- 喹硫平IC025为2.263、PRR为3.929;奥氮平IC025为0.259、PRR为1.020;齐拉西酮IC025为1.051、PRR为1.334。
临床怎么用
- 医生在处方这些抗精神病药时应考虑滥用/误用风险,尤其对有药物滥用史的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The study aim was to assess the abuse/misuse potential of second-generation antipsychotics (SGAPs) using VigiBase data. We extracted individual case safety reports of "Drug abuse, dependence and withdrawal" involving SGAPs up to June 2018. We assessed disproportionate reporting by calculating the information component, considering the lower end of the 95% credibility interval for the information component (IC025 ), and the proportional reporting ratio. We identified 1683 individual case safety reports recorded as "abuse, dependence and withdrawal" involving SGAPs, mainly quetiapine (n = 1089) and olanzapine (n = 209). The disproportional reporting indicators highlighted an association between "Drug abuse and dependence", and quetiapine, olanzapine and ziprasidone, as indicated by the IC025 (2.263, 0.259 and 1.051, respectively) and proportional reporting ratio values (3.929, 1.020 and 1.334, respectively). The abuse/misuse potential is confirmed for quetiapine and olanzapine and highlighted for the first time for ziprasidone. Physicians should consider these risks when prescribing these antipsychotics, especially to patients with history of drug abuse.
引用
- Roy S, Charreteur R, Peries M, et al. Abuse and misuse of second-generation antipsychotics: An analysis using VigiBase, the World Health Organisation pharmacovigilance database. Br J Clin Pharmacol. 2022. PMID: 35633029. doi:10.1111/bcp.15420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。